Intravenous human immunoglobulin (pH4) (Guangdong Shuanglin)

静注人免疫球蛋白 (pH4)（广东双林）

Report date: 2026/03/27 20:01:50

Base Information

Drug NameIntravenous human immunoglobulin (pH4) (Guangdong Shuanglin)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsPurpura, Thrombocytopenic, IdiopathicPolyradiculoneuropathy, Chronic Inflammatory Demyelinating
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryMainland China
Original Approved Date2020/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGuangdong Shuanglin Bio-Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangdong Shuanglin Bio-Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPurpura, Thrombocytopenic, IdiopathicPolyradiculoneuropathy, Chronic Inflammatory Demyelinating
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A